TCF3 Antibody

1. hnRNP H/F are important for maintenance and differentiation of embryonic stem cells and that this at least in part reflects a switch in TCF3 alternative splicing that leads to repression of CDH1/E-cadherin. PMID: 30115631
2. B-cell acute lymphoblastic leukemia patients with positive E2A-PBX1 fusion expression after transplant will have a poor prognosis. PMID: 29705861
3. It was concluded that the abnormal expression of endometrial E2A existed in mid-secretory endometrium of women with recurrent miscarriage, and there was a positive correlation between E2A and FOXP3, and E2A and CTLA-4, suggesting the possible regulatory role of E2A in endometrium receptivity. PMID: 29270752
4. TCF3 gene silencing inhibits esophageal cancer cells growth and proliferation, suppresses cell cycle progression, and promotes apoptosis. PMID: 28864779
5. suggested that the upregulation of TCF3 was a critical prognostic factor for nasopharyngeal carcinoma PMID: 28107608
6. Based on results, TCF3 is clearly associated with the progression of cervical squamous cell carcinoma. This is the first time that it has been reported that TCF3 can act as a tumor promoter in cervical cancer and thus might be of great significance in the prognosis of CSCC. PMID: 28604457
7. We conclude that inactivation of TCF3 contributes to oncogenic program of classical Hodgkin lymphoma PMID: 27166193
8. This is the first time the protein partners of either E2A-PBX1 or HOXA9 oncoproteins were identified using an unbiased biochemical approach. The identification of translation initiation factors associated with HOXA9 might indicate a novel function for HOX proteins independent of their transcriptional activity. PMID: 28707666
9. Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells. PMID: 27894958
10. MiR-138 may be a tumor suppressor and potential prognostic biomarker in cervical cancer. Its downstream target, TCF3, may also regulate cancer development in a reverse manner as miR-138. PMID: 28385388
11. High levels of TCF3 in gliomas promote glioma development through the Akt and Erk pathways. PMID: 27105323
12. TWIST1-E12 protein heterodimeric complexes may thus constitute the main active forms of TWIST1 with regard to senescence inhibition over the time course of breast tumorigenesis. PMID: 27237323
13. Review of the role of the E2A-PBX1 gene rearrangement in the prognosis of childhood acute lymphoblastic leukemia and its central nervous system relapse. PMID: 26509298
14. E47 is a novel substrate of PAK5, and PAK5-mediated phosphorylation of E47 promotes epithelial-mesenchymal transition. High expression of phospho-E47 was associated with an aggressive phenotype of colon cancer and metastasis. PMID: 26212009
15. We observed significant enrichment of the neuroactive ligand-receptor interaction pathway in TCF3-PBX1 as well as an enrichment of genes involved in immunity and infection pathways in ETV6-RUNX1 subtype PMID: 26237075
16. Over expression of E47 reprograms human pancreatic cancer cells to a quiescent acinar state with reduced tumorigenic potential. PMID: 25894862
17. Drug response profiling of matched patient-derived xenografts revealed a distinct profile for TCF3-HLF ALL with resistance to conventional chemotherapeutics but sensitivity to glucocorticoids. PMID: 26214592
18. When intensive chemotherapy was used, the TCF3-PBX1 was associated with a favorable outcome in childhood pre-B ALL. PMID: 25551271
19. Inhibitor of differentiation 4 (ID4) acts as an inhibitor of ID-1, -2 and -3 and promotes basic helix loop helix (bHLH) E47 DNA binding and transcriptional activity. PMID: 25778840
20. Data show that microRNAs miR-155 and miR-16 downregulate activation-induced cytidine deaminase (AID) and transcription factor E47 in B Cells through binding of the 3'-untranslated regions. PMID: 26223652
21. TCF3 is a novel susceptibility locus for Hodgkin lymphoma. PMID: 24920014
22. our data suggest a collaborative action between autophagy and ubiquitination in the degradation of E2A/Pbx1, thereby revealing a novel strategy for targeted preventive or treatment therapy on the pediatric ALL. PMID: 25615280
23. TCF3 rearrangement [t(1;19) (q23;p13)] was detected in 16 (20%) out of the 80 studied patients, and it was significantly associated with splenomegaly, lymphadenopathy, CNS infiltration. PMID: 25116187
24. Results show the up-regulation of TCF3, which is mainly caused by promoter hypomethylation, is one of the molecular mechanisms involved in the development and progression of colorectal cancer. PMID: 25375219
25. results suggest that E47 has diverse effects in T-ALL but that functional deficiency of E47 is not a universal feature of Lmo2-induced T-ALL. PMID: 25499232
26. In this study, we showed that TCF3-PBX1 positive pediatric BCP-ALL patients treated according to the JACLS ALL02 and CCLSG ALL2004 protocol had favorable outcomes PMID: 24578304
27. results suggest that E2A suppresses CRC cell metastasis, at least partially if not all, by inhibiting YAP expression PMID: 24369055
28. E2A is an independent prognostic factor for colorectal cancer patients and targets miR-320a to regulate cell proliferation of colon cancer cells. PMID: 24454819
29. Within the AETFC complex, AML1-ETO oligomerization is required for a specific interaction between the oligomerized NHR2 domain and a novel NHR2-binding (N2B) motif in E proteins, including HEB and E2A. Disruption of this interaction by point mutations abrogates AML1-ETO-induced hematopoietic stem/progenitor cell self-renewal and leukemogenesis. PMID: 23812588
30. In t(8;21) leukemia cells, the two E proteins, HEB and E2A, function as components of the stable AML1-ETO-containing transcription factor complex (AETFC). The AETFC components cooperatively regulate gene expression and contribute to leukemogenesis. PMID: 23812588
31. NF-kappaB potentiated the binding of E2A to an E-box motif located immediately downstream of the 2 closely-spaced transcription start sites for sustained 14-3-3gamma expression and CSR induction. PMID: 23851690
32. 4 patients with agammaglobulinemia had the same de novo mutation in the broadly expressed transcription factor E47. The mutant protein (E555K) was stable in patient-derived EBV-transformed cell lines and cell lines transfected with expression vectors. PMID: 24216514
33. E47 interacts with Id1 in E47 overexpressing MDCK cells that underwent a full epithelial-mesenchymal transition as well as in mesenchymal breast carcinoma and melanoma cell lines PMID: 23555842
34. E2A-PBX1 fusion gene caused by t(1;19)(q23;p13) may be a common genetic change in AIS and a survival determinant for female AIS patients at early stage. PMID: 23688269
35. High expression of TCF3 is associated with neuroblastoma progression. PMID: 23135478
36. We present the first evidence that the portion of E2A proteins found within the oncogenic fusion protein E2A-PBX1 and including the transcriptional activation domains can enhance the HAT activity of CBP/p300 PMID: 22387215
37. our findings show that the E2A proteins are acetylated at specific residues as a consequence of lysine acetyltranferases(CBP, p300 and PCAF ) recruitment PMID: 22207202
38. The molecular mechanism for this effect of EB1089 on the aromatase gene expression was found to be mediated by the vitamin D receptor (VDR), vitamin D receptor interacting repressor (VDIR) and Williams syndrome transcription factor (WSTF). PMID: 23085504
39. E2A-HLF sensitizes t(17;19)-positive acute lymphoblastic leukemia to graft-versus-leukemia effect by upregulating death receptors for TRAIL. PMID: 22743623
40. Absence of T cell precursor potential, both in vivo and in vitro, is due to low Notch1 expression and secondary to inhibition of E2A protein activity by members of the inhibitor of DNA binding (Id) protein family. PMID: 22972921
41. Protein inhibitor of activated STAT, PIASy regulates alpha-smooth muscle actin expression by interacting with E12 in mesangial cells. PMID: 22829926
42. These results thus implicate the E2A-CDKN1A transcriptional axis in the control of megakaryopoiesis and reveal the lineage-selective inhibition of this axis as a likely mechanistic basis for the inhibitory effects of cAMP signaling. PMID: 22514271
43. Transcription factor E2A plays critical roles in inducing immunoglobulin (Ig)kappa rearrangement by directly binding to and increasing chromatin accessibility at target gene segments. PMID: 22544934
44. These results for the first time demonstrate that E2A could in fact acts as a tumor promoter at least in prostate cancer. PMID: 22564737
45. studies show that the entire ensemble of Id proteins has the ability to interact with E47, identify factors that associate with E47, and reveal a spectrum of phosphorylated residues in E47, including an AKT substrate site PMID: 22354994
46. The E2A, a key transcription factor associated with the B-cell activation profile, regulates apoptosis in CLL and may contribute to disease pathology. PMID: 21551245
47. altering the balance between Id3 and E47 is both necessary and sufficient to regulate the cell cycle in PDA cell PMID: 21498546
48. E2A exhibits a tumor suppressor function in human lymphoid cells. PMID: 21788410
49. The results indicate that in cancer cells E2A, FOXO1 and FOXP1 regulate RAG1 and RAG2 expression, which initiates Ig gene rearrangement much in the way similar to B lymphocytes. PMID: 21655267
50. HEB and E2A-bind the SCA motif at regions overlapping SMAD2/3 and FOXH1 PMID: 21828274

Show More

Hide All

HGNC: 11633

OMIM: 147141

KEGG: hsa:6929

STRING: 9606.ENSP00000262965

UniGene: Hs.371282